Innovent Biologics, Inc. and RemeGen Co., Ltd., announced that they entered into a clinical trial collaboration and supply agreement with for the combination therapies of TYVYT® with RC88, a novel mesothelin-targeting antibody-drug conjugate, or RC108, a novel c-Met-targeting ADC, respectively, as potential treatment options for advanced solid tumors in China.
